课题基金 / 基金详情

Establish mentofthe minimally invasive treatments based on biological characteristics for advanceduro logical cancers.

Establish mentofthe minimally invasive treatments based on biological characteristics for advanceduro logical cancers.
建立基于晚期泌尿系统癌症生物学特性的微创治疗方法。
批准号:
07407046
负责人:
TACHIBANA Masaaki
金额:
$14.21万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (A)
财政年份:
1995
资助国家:
日本
项目状态:
已结题
起止时间:
1995 至 1997

项目摘要

项目成果

TACHIBANA Masaaki的其他基金

相关文献

中文摘要
翻译
本研究旨在确定反映泌尿系肿瘤侵袭性和恶性潜能的生物学特性,并试图建立新的治疗模式,即微创器官保留治疗。流式细胞仪DNA倍体分析对膀胱癌的诊断和预后有重要意义。联合使用组织学和流式细胞术参数可以提供有关膀胱癌患者临床结果的额外信息。我们还研究了多个染色体区域的杂合性缺失(LOH)作为膀胱癌可能的抑癌基因异常及其与临床预后的关系。高级别和侵袭性肿瘤包含多个抑制基因改变,显示出更大的遗传不稳定性。因此,对各种易感抑制基因区域的微卫星分析被认为对确定治疗方案…是有用的。膀胱癌患者更多的GES和预后因素。联合化疗治疗晚期膀胱癌已受到相当大的关注。然而,这种化疗的效果仍然不令人满意。提高这种治疗效果的关键在于确定构成靶肿瘤组织的癌细胞的增殖活性,并能够评估癌细胞对抗肿瘤药物的反应。令人信服的是,根据不同的时间表,多种药物治疗的不同有不同的疗效。在本研究中,通过对化疗药物的细胞动力学特性的分析,重点确定了联合化疗对膀胱癌细胞的最佳时间安排。甲氨蝶呤(MTX)联合化疗可显著增强长春花碱(VBL)和依托泊苷(EP)联合化疗对膀胱癌细胞的抗肿瘤作用,并诱导细胞发生明显的凋亡。核因子-kB是调节细胞因子基因表达的转录因子之一,最近被证明是一种诱导细胞凋亡的调节因子。在本研究中,我们确定产生系统因子的肿瘤的生长受核因子-kB的调节,因此用腺病毒载体抑制核因子-kB可以作为治疗膀胱癌相关副肿瘤综合征的有效的基因治疗方法。黑色素瘤抗原(MAGE)是从恶性黑色素瘤中克隆的一种肿瘤排斥反应抗原。近年来,MAGE在肿瘤免疫治疗方面引起了人们的极大关注,尤其是在诱导肿瘤特异性细胞毒性T细胞(CTL)方面,因为它广泛表达于各种肿瘤中,而在除睾丸和胎盘以外的正常细胞中不表达。此外,我们还研究了核因子-kB是否可以调节肿瘤坏死因子-α耐药的前列腺癌细胞的生长和凋亡。NFkB激活可阻止肿瘤坏死因子-α诱导的DU-145和PC-3细胞死亡。因此,抑制核因子-kB的激活可能是治疗肿瘤坏死因子-α耐药的前列腺癌细胞的有效方法。较少
英文摘要
This study was designed to determine the biological characteristics which reflect invasiveness and malignant potential of urological cancers and try to establish new therapeutic modalities as minimally invasive organ preserving treatments. Flow cytometric DNA ploidy analysis for human bladder cancers may provide significant diagnostic and prognostic potential. Combined use of histological and flow cytometric parameters may offer additional information regarding the clinical outcome for bladder cancer patients. We also studied the loss of heterogygosity (LOH) of the multiple chromosome regions as possible suppressor gene abnormalities on human bladder cancers and their relation ships with clinical outcomes. High-grade and aggressive tumors contain multiple suppressor gene alterations that demonstrate a greater genetic instability. Therefore, a microsatellite analysis of a variety of susceptible suppressor gene regions is considered to be useful in determining both the therapeutic strate … More gies and prognostic factors for patients with bladder cancer. Considerable attention has been given to combination chemotherapy for the treatment of advanced bladder cancer. However, the effectiveness of this chemotherapy remains less than satisfactory. The key to enhancing the efficacy of this treatment lies in ascertaining the proliferating activities of cancer cells composing target tumor tissue and in being able to gauge the response to antitumor agents of cancer cells. It is convincing that there are different efficacies following a variation in multidrug treatment depending on its scheduling. In the present study, emphasis was placed on determining the optimal time schedule of combination chemotherapy administered against bladder cancer cells using an analysis of cell kinetic characteristics of the chemotherapeutic agents. Methotrexate (MTX) pretreatment can significantly enhance the antitumor effects of vinblastine (VBL) and etopocide (EP) when compared with simultaneous treatment and/or the reversed schedule in combined chemotherapy with MTX and EP/VBL against bladder cancer cells, with induction of significant apoptosis. Nuclear factor kappa B (NF-kB) is one of the transcription factors which regulate cytokine gene expression and it was very recently shown to be a regulatory factor for the induction of apoptosis. In the present study, we determined that the growth of sytokine producing tumors was regulated by NF-kB and therefore the inhibition of NF-kB by adenovirus vector can be used as an effective gene therapy for the treatment of cytokine producing bladder cancer associated paraneoplastic syndromes. Melanoma antigen (MAGE) is known as a tumor rejection antigen cloned originally from malignant melanoma. MAGE has recently attracted great attention in cancer immunotherapy, especially regarding the induction of tumor specific cytotoxic T-cells (CTL) because it is widely expressed in various tumors but not in normal cells except for the testis and placenta.Additionally, we investigated whether or not growth and apoptosis can be regulated by NF-kB on TNF-alpha-resistant prostate cancer cells. NFkB activation prevents TNF-alpha-induced cell death in DU-145 and PC-3 cells. As a result, the inhibition of NF-kB activation may thus be an effective therapy for TNF-alpha-resistant prostate cancer cells. Less
期刊论文(30)
专著(0)
科研奖励(0)
会议论文
Tachibana M: "Prognostic significance of flow cytometric deoxyribonucleic acid analysis for patients with superficial bladder cancers" Cancer Detec Prev. in press
Tachibana M:“流式细胞仪脱氧核糖核酸分析对浅表性膀胱癌患者的预后意义”Cancer Detec Prev。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Jun Nakashima et al.: "The value of serum carboxyterminal propeptide of type 1 procollagen in predicting Bone Metastases in prostate cancer." J.Urol.(in press).
Jun Nakashima 等人:“1 型前胶原血清羧基末端前肽在预测前列腺癌骨转移中的价值。”
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Tachibana M: "Role of proliferative activity estimated by bromodeoxyuridine labeling indexin determining predictive factors of recurrence in superficial intermediately malignant bladder tumors." J Urol. 156(10). 63-63 (1996)
Tachibana M:“通过溴脱氧尿苷标记指数估计的增殖活性在确定浅表中度恶性膀胱肿瘤复发的预测因素中的作用。”
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
共 30 条
    Tumor specific immunotherapy using dendritic cells generated from allogeneic peripheral stem cell.
    • 批准号:
      14370520
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $9.22万
    • 财政年份:
      2002
    • 负责人:
      TACHIBANA Masaaki
    • 依托单位:
    HLA restricted tumor specific antigen epitope pulsed autologous dendritic cell vaccine treatment for hormone refractory prostate cancer
    • 批准号:
      12671557
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.56万
    • 财政年份:
      2000
    • 负责人:
      TACHIBANA Masaaki
    • 依托单位:
    Induction of apoptosis against cytokine-producing urological cancer
    • 批准号:
      10671493
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.11万
    • 财政年份:
      1998
    • 负责人:
      TACHIBANA Masaaki
    • 依托单位:
    Studies on objective indicator for predicting malignant potential of bladder cancer.
    • 批准号:
      04454409
    • 项目类别:
      Grant-in-Aid for General Scientific Research (B)
    • 资助金额:
      $3.9万
    • 财政年份:
      1992
    • 负责人:
      TACHIBANA Masaaki
    • 依托单位: